Show simple item record

 
dc.contributorDepartament de Salut
dc.date.accessioned2018-03-05T13:37:48Z
dc.date.available2018-03-05T13:37:48Z
dc.date.issued2017-03
dc.identifier.citationRiscos associats a l'ús d'antidepressius en joves. Barcelona: Servei Català de la Salut; 2017.
dc.identifier.urihttps://hdl.handle.net/11351/3340
dc.descriptionTeens; Depression; Pharmacological treatment
dc.description.abstractSystematic reviews of clinical trials indicate that in children and adolescents the efficacy of antidepressants is doubtful or invalid, which increases the risk of ideation and attempted suicide, as well as other neuropsychiatric disorders. However, these drugs are still prescribed to children and young people. The only authorized antidepressants in children and adolescents are fluoxetine (for depression), sertraline (for obsessive-compulsive disorder), and imipramine, nortriptyline and clomipramine (for nocturnal enuresis)
dc.language.isocat
dc.publisherServei Català de la Salut
dc.publisherDepartament de Salut
dc.publisherFundació Institut Català de Farmacologia
dc.relation.ispartofPla d’Informació i Detecció de Problemes de Seguretat Clínica en Recepta Electrònica
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceScientia
dc.subjectAntidepressius - Efectes secundaris
dc.subjectAdolescents - Salut mental
dc.subjectDepressió psíquica en els adolescents
dc.subject.meshAntidepressive Agents
dc.subject.mesh/adverse effects
dc.subject.meshAdolescent
dc.titleRiscos associats a l'ús d'antidepressius en joves
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsantidepresivos
dc.subject.decs/efectos adversos
dc.subject.decsadolescente
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record